Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single-arm study of TACE + anlotinib + TQB2450 as first-line treatment for advanced hepatocellular carcinoma
ChiCTR2200056222Phase 4Recruiting
- Sponsor
- Henan Cancer Hospital
- Start
- Jun 2022
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of anlotinib and benmelstobart in hepatocellular carcinoma (HCC), sponsored by Henan Cancer Hospital. Primary endpoint: Objective response rate. Started Jun 2022; status: recruiting.
02
Drugs
anlotinibbenmelstobart
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on ChiCTR2200056222.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2200056222.